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CAD is a large multifunctional polypeptide that initiates and controls the de novo biosynthesis of pyrimidines
in animals. In this issue of Structure, Grande-Garcı´a and colleagues provide the first atomic information of
this antitumoral target by reporting the crystal structure of the dihydroorotase domain of human CAD.Nucleotides are biologically ubiquitous
substances that participate in nearly all
biochemical processes; they form the
monomeric units of nucleic acids or the
nucleoside triphosphates among others.
Their relevance in cellular metabolism is
indicated by the fact that nearly all cells
can synthesize them both de novo and
from degradation products of nucleic
acids. Although the de novo synthesis of
pyrimidine nucleotides (Figure 1A) is
conserved in nearly all organisms, the or-
ganization of the responsible enzymes is
not. In animals, the first three activities
of the pathway, glutamine-dependent
carbamoyl phosphate synthetase (GLN-
CPSase), aspartate transcarbamylase
(ATCase) and dihydroorotase (DHOase),
are catalyzed by CAD, a 243 kDa
multifunctional polypeptide (Figure 1B)
that controls the flux of the pathway and
is under strict allosteric control. In pro-
karyotes and plants, on the other hand,
GLN-CPSase, ATCase, and DHOase
are encoded as independent proteins,
whereas fungi have a CAD-like protein
with GLN-CPSase and ATCase activities
linked by an inactive DHOase-like do-
main, and the DHOase activity is provided
by an independent protein.
The required upregulation of CAD for
cellular proliferation and its phosphoryla-
tion through different signaling cascades
(Figure 1B) has awakened the interest in
its potential use as a target for new thera-
peutic treatments. In fact, the discovery of
CAD tracks back to the 1970s, when it
was found to be the target of an antitu-
moral compound. At that time, several
groups had reported that the CPSase,
ATCase, and DHOase activities in dif-
ferent animal cells associated in a com-
plex. But, it was in 1977 that George R.
Stark and colleagues discovered that thethree activities were carried on a single
polypeptide chain, named CAD (an
acronym of the first letters of each enzy-
matic activity) (recalled in Stark, 2005).
Interested in the carbamylation of inter-
mediate metabolites in the cell, Stark
and Collins synthesized N-phosphonace-
tyl-L-aspartate (PALA), postulating that
it would be a transition state analog
of ATCase. Following Linus Pauling’s
reasoning that an analog of the transition
state would be a potent reversible inhi-
bitor, they discovered that PALA was
indeed a potent inhibitor of Escherichia
coli ATCase (Collins and Stark, 1971)
and aided in revealing the catalytic and
allosteric mechanisms of this enzyme.
Surprisingly, they also observed that
PALA were able to penetrate into mouse
cells, block the de novo biosynthesis of
pyrimidines, and arrest proliferation and
tumor growth. However, a very small
number of cells overcome the inhibitory
effect of PALA by producing high levels
of ATCase (up to 5% of soluble protein)
(Kempe et al., 1976). When the ATCase
activity was isolated from these cell lines,
it was found to be associated with
CPSase and DHOase on a single multi-
functional polypeptide, which self-associ-
ated mainly as a mixture of trimers and
hexamers (Coleman et al., 1977). Later
work from Stark’s group demonstrated
that the resistance of the cells to PALA
responded to an amplification (up to
100-fold) of the CAD gene (Wahl et al.,
1979), providing first evidence of gene
amplification in mammalian cells, a com-
mon hallmark of cancer cells.
Over the past 30 years since this pio-
neering work, considerable efforts have
been made to elucidate the organization
and architecture of CAD (reviewed in
Evans, 1986). The extreme sensitivity ofStructure 22, February 4, 2014CAD to proteases and the analysis of
the fragments proved that CAD had a
well-defined modular structure, with
each activity carried out by a different
compactly folded domain (Figure 1B)
(Kim et al., 1992). The DHOase and
ATCase domains are particularly resistant
to further proteolytic cleavage and stable
over time, which helped their isolation
and characterization. The ATCase domain
of CAD was shown to form stable trimers
that are key for the oligomerization of
CAD (Qiu and Davidson, 2000), which
suppors that the basic unit of the complex
is a trimer. The DHOase domain was
shown to form homodimers in solution,
although the subunits interactions were
not very strong (Kelly et al., 1986), and
this suggested a model where two CAD
trimers could dimerize through the
DHOase domains to form a hexamer.
Although some structures of CPSase,
ATCase, and DHOase from bacteria and
archaea are available, up to now, there
was no detailed structural information
about CAD. Thus, clearly understanding
CAD requires characterizing the inde-
pendent functional domains, but, more
importantly, it requires information about
the arrangement of the domains in the
context of an 1.5 MDa hexameric
particle.
In this issue of Structure, Grande-
Garcı´a et al. (2014) enrich the range of
current structural information about CAD
by determining 15 different crystal struc-
tures of the DHOase domain of human
CAD at a resolution better than 1.5 A˚
(Figure 1C). Overall, the structure of
huDHOase reveals a dimeric protein,
with each subunit exhibiting a (b/a)8-
barrel fold characteristic of the amido-
hydrolase superfamily of enzymes that is
similar to bacterial DHOases. The detailedª2014 Elsevier Ltd All rights reserved 179
Figure 1. CAD and De Novo Biosynthesis of Pyrimidines
(A) The synthesis of UMP involves six reactions. In animals, the first three steps are catalyzed byCAD (highlighted in a yellow box). The fourth step is catalyzed by a
dehydrogenase located in the inner mitochondrial membrane. The transfer of PRPP and the decarboxylation of the pyrimidine ring are catalyzed by a bifunctional
enzyme, UMP synthetase. The CPSase activity of CAD is the rate-limiting step of the pathway and is also allosterically inhibited by the final product, UTP, and
activated by PRPP (dashed lines).
(B) Arrangement of the functional domains in CAD. The phosphorylation sites for the corresponding kinases are indicated.
(C) Structure of human DHOase dimer reported by Grande-Garcı´a et al. (2014).
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Previewscharacterization of the human enzyme,
which combines structural characteri-
zation, site-directed mutagenesis, and
activity assays, demonstrates that, con-
trary to previous studies suggesting that
mammalian DHOase contained one Zn2+
ion bound per monomer (Kelly et al.,
1986), the active site of human DHOase
contains two Zn2+ ions bridged by a
carboxylated lysine in an identical posi-
tion as those observed in the structure of
E. coliDHOase. Similar to E. coliDHOase,
CAD DHOase also has a flexible loop that
opens and closes over the active site and
participates in the catalytic cycle. Thus,180 Structure 22, February 4, 2014 ª2014 Elsthe authors propose that both E. coli
DHOase and CAD share a common
catalytic mechanism that has been exqui-
sitely conserved despite the evolutionary
divergence.
Moreover, the authors identify some
unique features in the structure of human
CAD DHOase, such as the binding of a
third Zn2+ ion to a rare histidinate ion at
the active site, and explore their participa-
tion in the reaction by a thorough combi-
nation of mutagenesis, biochemical, and
structural approaches. They also report
that the dimerization mode of CAD
DHOase differs from those observed inevier Ltd All rights reservedthe bacterial enzymes and that the human
DHOase dimers do not support previous
models on CAD architecture based on
the interaction between bacterial DHOase
and ATCase enzymes. Furthermore, the
comparison with the bacterial homologs
reveals new unnoticed features of the
bacterial DHOases that lead the authors
to propose a new classification of the
DHOase family that should further aid
in understanding the gene fusion event
that gave origin to CAD.
More detailed structural information
about the other functional domains and/
or the characterization of the full-length
Structure
Previewsparticle, perhaps by electron microscopy,
will be required to further understand the
architecture and functioning of CAD.
This paper, however, lays the foundation
for the molecular comprehension of this
crucial and fascinating multifunctional
complex.
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